secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001711279-23-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023
----------------------------------------------------------------------------

- Cash, cash equivalents and investments $383.8M at Dec 31, 2022.
- Net loss $140.0M for FY2022 vs $69.6M in FY2021; diluted EPS $(5.49) vs $(3.13).
- B-VEC PDUFA date set for May 19, 2023; all FDA inspections complete.
- Phase 3 GEM-3 trial results for B-VEC published in New England Journal of Medicine.
- Plans to initiate four pipeline trials in 2023 across dermatology, respiratory, aesthetics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/krys-20230227.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer